NERAZZU-25

Treatment of essential hypertension in adults and in children and adolescents 6-18 years of age.
Treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus with proteinuria ?0.5 g/day.
Treatment of chronic heart failure in adult patients when treatment with Angiotensin converting enzyme (ACE) inhibitors is not considered suitable due to incompatibility, especially cough, or contraindication.
Reduction in the risk of stroke in adult hypertensive patients with left ventricular hypertrophy documented by ECG.

This is only the preview. Please check here for the full indication.

Anatomical Therapeutic Chemical: C
Dosage form: Film coated tablet
Packaging: 10's x 10
Therapeutic area: Active pharmaceutical ingredient: